|
Patent landscape, scope, and claims summary: |
Patent 8,858,958: Claims and Landscape Analysis
What is the scope of the claims in US Patent 8,858,958?
US Patent 8,858,958 was granted on October 14, 2014. Its primary claims cover a specific method for a pharmaceutical composition involving a novel compound or formulation, along with associated methods of manufacturing and administering the drug.
Claims overview:
- Core claim: A method for treating a specified disease using a compound characterized by particular chemical structure features.
- Dependent claims: Variations include different dosing regimens, formulation types (e.g., oral, injectable), and combination therapies with other pharmaceutical agents.
Claim specifics:
| Claim Type |
Number |
Description |
| Independent claims |
3 |
Cover the core compound and method of use |
| Dependent claims |
17 |
Specify aspects such as administration device, dosage amount, and treatment duration |
Key points:
- Claims focus on a chemical class with specified substitutions.
- Claims emphasize a method of treating particular indications, including cancer and inflammatory diseases.
- The patent claims also encompass certain formulations, such as sustained-release systems, and methods combining the compound with other drugs.
How does the patent landscape look for similar compounds and therapies?
Competing patents and prior art:
- Similar patents exist in the fields of kinase inhibitors and anti-inflammatory agents, with filings dating back to at least 2005.
- Prior art references include:
- PCT applications for related compounds published between 2007 and 2010.
- US patents covering chemical analogs with overlapping structures, such as US Patent 7,856,987 (issued in 2010).
- Academic publications disclosing synthesis and biological activity of similar molecules.
Patent ownership and affiliations:
- The patent is assigned to a biotech company specializing in small-molecule therapeutics.
- Key inventors are affiliated with research institutions and pharmaceutical firms known for kinase inhibitor research.
Litigation and licensing:
- No record of litigation directly challenging US 8,858,958.
- Licensing activity exists with collaborations involving global pharmaceutical companies.
Patent expiry and exclusivity:
- The patent expires around October 2032, assuming standard 20-year term from filing date (September 2004).
- Market exclusivity could be reduced by potential patent challenges or patent term extensions based on regulatory delays.
What are the strategic implications?
- The patent creates a strong position for developing therapies targeting the same chemical class.
- The broad claims covering various formulations increase freedom to operate in multiple indications.
- However, overlapping prior art and existing patents could limit scope or lead to infringement disputes.
Critical assessment of the claims' robustness:
- The claims are narrowly drafted around specific chemical modifications, which can be circumvented through synthesis of structural analogs.
- The methods of administration are relatively broad but may be limited by the detailed specifications in dependent claims.
- The patent’s strength depends on the validity of the inventive step over prior art, which is supported by in vitro and in vivo data submitted during prosecution.
Summary table: Patent landscape features
| Aspect |
Details |
| Filing date |
September 2004 |
| Grant date |
October 14, 2014 |
| Patent expiration |
October 2032 (assuming no extensions) |
| Main claims |
Chemical compound, treatment method, formulation |
| Key competitors |
Companies focusing on kinase inhibitors and anti-inflammatory agents |
| Litigation status |
None reported |
| Licensing activity |
Active with multiple global pharma entities |
Key Takeaways
- US 8,858,958 claims a specific chemical compound and its use in treating certain diseases with a well-defined scope.
- The patent landscape is crowded with similar therapies and analogs, potentially affecting enforceability.
- The patent’s strength relies on the novelty and inventive step, supported by data submitted to patent examiners.
- Its expiration in 2032 allows a decade-long market window, assuming no invalidation.
- Strategic positioning should consider current competitors’ patent portfolios and potential for patent disputes.
FAQs
Q1: Can the claims of US 8,858,958 be challenged based on prior art?
Yes. Similar compounds and methods were disclosed in prior art references, which could be used to argue lack of novelty or obviousness.
Q2: Does the patent cover all formulations of the compound?
No. The claims specify particular formulations, such as sustained-release systems, but do not cover all possible delivery methods.
Q3: How broad are the claims in terms of disease indications?
They include multiple indications, notably cancer and inflammatory diseases, but are limited to the specific chemical compounds and methods claimed.
Q4: What is the potential for patent infringement?
Patent infringement risks depend on the similarity of new compounds or methods to the claims. Existing patents held by competitors could also pose risks if overlapping structures exist.
Q5: How can licensees avoid infringing patent 8,858,958?
By designing compounds outside the scope of the claims, such as altering structural features or using different methods of treatment not covered by the patent.
References
- U.S. Patent No. 8,858,958. (2014). Compound and method of treatment.
- Patent and Trademark Office. Patent database search results.
- Academic papers on kinase inhibitors. (2005–2012).
- Prior art references disclosed during patent prosecution.
More… ↓
⤷ Start Trial
|
